Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

L5025

Sigma-Aldrich

Leflunomide

Immunosuppressant

Synonyme(s) :

5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C12H9F3N2O2
Numéro CAS:
75706-12-6
Poids moléculaire :
270.21
Numéro MDL:
MFCD00867593
Code UNSPSC :
12352202
ID de substance PubChem :
24278516
Nomenclature NACRES :
NA.77

Niveau de qualité

200

Pureté

≥98% (TLC)

Forme

powder

Pf

166.5 °C

Solubilité

methanol: 19.60-20.40 mg/mL, clear, colorless to faintly yellow

Mode d’action

enzyme | inhibits

Température de stockage

2-8°C

Chaîne SMILES 

Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F

InChI

1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)

Clé InChI

VHOGYURTWQBHIL-UHFFFAOYSA-N

Informations sur le gène

human ... DHODH(1723)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

By virtue of its immunosuppressant effects, leflunomide has found use in organ transplantation and treatment of rheumatoid arthritis and other autoimmune diseases.

Actions biochimiques/physiologiques

Immunosuppressive; inhibits T and B cell proliferation. Activity is attributed mainly to its metabolite, a malononitrile derivative, which is believed to inhibit dihydroorotate dehydrogenase (in the de novo pyrimidine synthesis pathway) as well as several protein tyrosine kinases.

Pictogrammes

Skull and crossbones
GHS06

Mention d'avertissement

Danger

Mentions de danger

H301,H315,H319,H335

Classification des risques

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 9

1 of 9

Sulfasalazine 97.0-101.5%

Sigma-Aldrich

S0883

Sulfasalazine

Sulfasalazine British Pharmacopoeia (BP) Reference Standard

BP779

Sulfasalazine

Sulindac ≥98.0%

Sigma-Aldrich

S8139

Sulindac

L-Dihydroorotic acid ≥99%

Sigma-Aldrich

D7128

L-Dihydroorotic acid

Decylubiquinone ≥97% (HPLC)

Sigma-Aldrich

D7911

Decylubiquinone

Mdivi-1 ≥98% (HPLC), powder

Sigma-Aldrich

M0199

Mdivi-1

Uridine powder, BioReagent, suitable for cell culture

Sigma-Aldrich

U3003

Uridine

Méthotrexate hydrate powder, BioReagent, suitable for cell culture, ≥98% (HPLC)

Sigma-Aldrich

M8407

Méthotrexate hydrate

Uridine ≥99%

Sigma-Aldrich

U3750

Uridine

J M Kremer et al.
Clinical and experimental rheumatology, 22(5 Suppl 35), S95-100 (2004-11-24)
Leflunomide was first shown to have disease-modifying properties in a rat model of adjuvant-induced arthritis. Leflunomide has been subsequently used with success in several animal models of tissue and organ allograft and of autoimmune disease including collagen- and adjuvant-induced arthritis
K F Siemasko et al.
Transplantation, 61(4), 635-642 (1996-02-27)
Leflunomide is an immunosuppressive drug capable of inhibiting cellular and humoral mediated responses in vivo. The mechanism responsible for suppression of B cell antibody responses in vivo has not been identified. In this study we demonstrate that leflunomide functions to
X Xu et al.
Biochemical pharmacology, 52(4), 527-534 (1996-08-23)
Previous studies have demonstrated that the active metabolite of leflunomide, A77 1726 [N-(4-trifluoromethylphenyl-2-cyano-3-hydroxycrotoamide)], is capable of inhibiting the activities of tyrosine kinases and dihydroorotate dehydrogenase (DHO-DHase). In the present study, we define the relative contribution of these activities to the
T R Brazelton et al.
Current opinion in immunology, 8(5), 710-720 (1996-10-01)
Among all the new immunosuppressive molecules being investigated either preclinically or clinically, four stand out: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide (and its malononitriloamide analogs). Each drug has distinct mechanisms of immunosuppressive action, and in the past year
Nicolae Leca
Current opinion in organ transplantation, 14(4), 370-374 (2009-06-11)
Leflunomide has been used off-label in renal transplantation because of the attractive combination of antiviral and immunosuppressive effects. This study intends to review the clinical applications of leflunomide with interest to transplantation. In renal transplantation, particularly in BK nephropathy, the
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique